A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

This study is testing a new combination of two drugs — HS-20117 and aumolertinib — as a first-line treatment for advanced lung cancer (non-squamous NSCLC) that has a specific genetic mutation in a gene called EGFR. These drugs work by targeting the cancer's growth signals. **You may be eligible if...** - You are 18–75 years old - You have been newly diagnosed with advanced or metastatic non-small cell lung cancer with a sensitive EGFR mutation - You have not yet received any treatment for your advanced lung cancer - You have at least one measurable tumor on scans - Your general health is good (ECOG 0 or 1) - Your life expectancy is more than 12 weeks - You are willing to use contraception if applicable **You may NOT be eligible if...** - You have previously received MET-targeted therapy or EGFR antibody treatments - You have significant fluid build-up around your lungs or heart requiring treatment - You have significant side effects from prior cancer therapy - You have another primary cancer in your history (with some exceptions) Talk to your doctor to see if this trial is right for you.